



Article  (Published Version)
http://sro.sussex.ac.uk
Haddadin, Yazan, Katarey, Dev, Sachdeva, Manavi, Vickers, Laura, Kaur, Ishleen, Hashim, 
Ahmed and Verma, Sumita (2020) Does regulating the sale of high-strength beer and cider 
impact hospital admissions with decompensated alcohol-related liver disease: A retrospective 
cohort study. Clinical Medicine, 20 (3). pp. 308-312. ISSN 1470-2118 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/89316/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
308 © Royal College of Physicians 2020. All rights reserved.
ORIGINAL RESEARCH Clinical Medicine 2017 Vol 17, No 6: 308–8ORIGINAL RESEARCH Clinical Medicine 2020 Vol 20, No 3: 308–12
Does regulating the sale of high-strength beer and cider 
impact hospital admissions with decompensated alcohol-
related liver disease: A retrospective cohort study
Authors: Yazan Haddadin,A Dev Katarey,B Manavi Sachdeva,C Laura Vickers,C Ishleen Kaur,C Ahmed HashimB and 
Sumita VermaD
Authors: Acore medical trainee, Brighton and Sussex University 
Hospitals NHS Trust, Brighton, UK; Bacademic specialist trainee, 
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK 
and Brighton and Sussex Medical School, Brighton, UK; Cfoundation 
year trainee, Brighton and Sussex University Hospitals NHS Trust, 
Brighton, UK; Dprofessor in hepatology, Brighton and Sussex 
University Hospitals NHS Trust, Brighton, UK
Objective
‘Sensible on Strength’ (SoS), a local public health initiative, is 
aimed at reducing high-strength beer and cider availability. 
The objective of this study was to assess its impact on local 
hospital admissions with alcohol-related liver disease (ALD) 
and on drinking behaviour.
Design
This was a retrospective cohort study in patients admitted 
with decompensated ALD, 3 years before and 3 years after the 
introduction of the SoS initiative.
Hospital records of 143 index admissions with 
decompensated ALD were reviewed. Outcomes measures 
were the severity of liver disease on admission and mortality 
(inpatient and long-term), and change (if any) in alcohol 
drinking behaviour.
Results
Comparing patients admitted in both phases, there were 
no significant differences in liver prognostic scores, liver-
related complications, length of stay and inpatient/long-term 
mortality (p>0.05). However, the SoS initiative was associated 
with a 33% move away from beer and cider consumption 
(36.3% vs 54.0%; p=0.034), but without a significant change 
in units of alcohol consumed. The Model for End-stage Liver 
Disease (MELD) score was the only independent predictor of 
inpatient mortality (odds ratio 1.25; p=0.025).
Conclusion
Despite having no apparent impact on the clinical spectrum of 
local ALD admissions, it is conceivable that longer follow-up is 












Alcohol misuse continues to be one of the leading causes of 
liver disease in the UK, with over one-third of a million hospital 
admissions in England between 2016 and 2017 due to an alcohol-
related primary condition. Moreover, alcohol-specific mortality is 
also on the rise, with 5,507 directly attributable deaths in England 
alone in 2016 (up by 11% compared with 2006).1
In addition to the human toll, alcohol has a huge societal 
impact. A report published in 2016 estimates the annual cost 
of alcohol to be between 1.3% and 2.7% of gross domestic 
product.2
The burden of alcohol-related liver disease (ALD), however, is 
not shared equally between different regions of the UK or, indeed, 
different socioeconomic groups. Public Health England (PHE) have 
identified certain high-risk areas for ALD. Coastal towns, where 
night-time drinking plays a big part in the economy, and deprived 
areas, with high prevalence of harmful drug use, seem to be 
particularly susceptible.1
Brighton and Hove in the UK is home to the most populous 
seaside community in England and Wales according to the 
2011 census.3 A city with a population of almost 300,000 
people, two universities and a large lesbian, gay, bisexual and 
transgender community, its economy relies heavily on tourism and 
entertainment, of which night-time drinking plays a large part. 
There is no surprise, therefore, that locally they have one of the 
highest rates of alcohol-specific mortality (16.1/100,000; national 
average 10.6/100,000) and number of admission episodes for 
alcohol-specific conditions (697/100,000; national average 
570/100,000) in south-east England.4
As highlighted by the recent Lancet report on liver disease, 
strong cheap alcohol plays a particularly damaging role, a fact 
acknowledged by government legislators.1
Scotland has been a major lead in the UK with the introduction 
of a national minimum unit pricing in May 2018. But local 
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ALD was defined as long-standing alcohol excess (>14 units / 
>112 g in 1 week regardless of gender) and/or if medical records 
stated alcohol as the aetiology of liver disease.11
Data collection
Alcohol history was obtained from the medical records. Our 
hospital admission pro forma has a specific section for this. We 
recorded data on duration, nature and amount of alcohol being 
consumed. If there was a discrepancy in this data between the 
admitting medical and gastroenterology/hepatology team, the 
latter's version was recorded. We also collected data on patients 
who, as a result of feeling unwell, reduced their alcohol intake to 
the point of abstinence prior to admission. If a patient expressed 
a preference to more than one type of alcohol, this was also 
noted.
In addition to the alcohol history and outcome measures 
mentioned, the following data were retrospectively collected 
from medical and electronic records: patient demographics, 
comorbidities, presence of ascites, infections, acute kidney 
injury (AKI), HE, portal hypertension-related gastrointestinal 
(GI) haemorrhage, and the number and duration of subsequent 
hospital admissions.
Overall survival was calculated from the date of hospitalisation 
until May 2018 and censored at death (based on hospital 
electronic records). Cause of death was obtained largely from 
hospital records and inpatient death certificates. Deaths arising 
from hepatocellular carcinoma (HCC), liver failure and portal 
hypertension-related GI bleeding were defined to constitute 
liver-related mortality. Patients with any other form of coexistent 
chronic liver disease (viral hepatitis, iron overload, and biliary or 
autoimmune disease) were excluded.
There are approximately 323 premises that sell alcohol in the 
city. Table 1 shows the timeline of those premises that joined 
the SoS scheme from 2013 to the time of writing. The campaign 
therefore saw the participation of only 154 (41%) premises 
during our study period, although this had increased to 74% by 
2019.12
strategies could have the potential to expand the benefits seen 
with national initiatives by tackling the availability and marketing 
of cheap high-strength beverages. A report suggests that as 
high-strength alcohols have become more affordable since 1980, 
alcohol-related deaths in England and Wales have more than 
trebled.5
In November 2013, the Brighton and Hove local city council 
launched a voluntary ‘Sensible on Strength’ (SoS) campaign to 
encourage off-licences against selling high-strength beer, lager 
or cider (above 6% alcohol by volume) and implement other 
good practices including a strict refusal policy, round-the-clock 
closed-circuit television monitoring and displaying of an SoS 
sticker. Two years following the initiative, there has been a 31% 
drop in street drinking. Other cities (Manchester) adopting similar 
initiatives (‘Reduce the Strength’) also observed a fall in alcohol-
related crime in intervention compared to control areas that 
continued to sell cheap high-strength beverages (41% vs 15%, 
respectively).2
The aim of this study was to assess the impact of the SOS 
initiative on local hospital admissions with ALD as well as on 
alcohol drinking behaviour in this subgroup of patients.
Patients and methods
This retrospective cohort study was conducted at a large teaching 
hospital in south-east England from 3 years before (phase 1) to 3 
years after (phase 2) the launch of the SoS initiative (November 
2010 to November 2016). Patients with a primary coded diagnosis 
of ALD (all ‘K70’ International classification of diseases, 10th 
revision (ICD-10) codes) during the study period were identified 
from the hospital's database.6 Their medical and electronic 
records were then retrospectively reviewed to identify those with 
an index presentation with decompensated cirrhosis.
Decompensated cirrhosis was defined by the presence of one 
or more of the following on admission: variceal bleeding, ascites, 
hepatic encephalopathy (HE) and jaundice, with an admission 
Child–Pugh score (CPS) of ≥7.7 CPS can be difficult to determine 
retrospectively as it includes subjective assessment of ascites and 
HE. Severity of ascites and HE were based on a senior clinician's 
review as documented in the medical records and, if needed, 
supported by radiological data. Most individuals with HE fulfilled 
study inclusion criteria, irrespective of scores allocated for HE. 
We selected decompensated cirrhosis as an eligibility criterion to 
ensure that the hospital admissions were directly related to the 
liver disease.
While there are now accepted clinical criteria for the diagnosis 
of alcoholic hepatitis, unfortunately about 50% of our cohort did 
not have an aspartate transaminase (AST) performed as only the 
alanine transaminase (ALT) is included in the standard liver panel 
at our hospital.8 We therefore did not stratify patients based on 
absence or presence of alcoholic hepatitis.
Our outcome measures were to assess impact of SoS initiative 
on:
> the severity of liver disease at index presentation with 
decompensated ALD as assessed by liver prognostic scores 
(CPS, Model for End-stage Liver Disease (MELD) score and UK 
Model for End-stage Liver Disease (UKELD) score), length of 
hospital stay, and inpatient and long-term mortality
> change (if any) in alcohol drinking behaviour in our patient 
group.9,10
Table 1. Number of premises signed up to the 
Sensible on Strength scheme by year
Year Official 
members 













2013–14 79 0 79 (24.5)
2014–15 119 0 119 (36.8)
2015–16 131 23 154 (47.7)
2016–17 159 39 198 (61.3)
2018–19 178 48 226 (70.0)
2019–20 191 49 240 (74.3)
SoS = Sensible on Strength.
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Statistical analysis
Data are presented as mean (± standard deviation), median 
(interquartile range) or number (%) and all reported p values 
are two-tailed. The Mann–Whitney U test and Student's 
t-test were used to compare non-parametric and parametric 
continuous variables, respectively, and categorical data were 
compared using the χ2 test. Kaplan–Meier (KM) survival tables 
and curves were generated and factors compared using the 
logrank test. Binary logistic regression analysis was performed 
to identify factors associated with in-hospital mortality. 
Parameters with p values <0.10 in univariate analysis were 
selected for inclusion in a multivariable regression model to 
determine independent predictors of in-hospital mortality. 
Survival analyses were performed in the whole cohort and 
statistical analyses were undertaken using SPSS Version 25.0 
(IBM Corp, Armonk, USA).
This study was classified as service evaluation by our institute's 
research and development department and formal ethics approval 
was not deemed necessary.
Results
During the study period, we identified 612 individual patients 
with an ALD coded admission who lived within the SoS initiative's 
catchment area. Of these, we excluded 462: incorrectly coded as 
having chronic liver disease or the extent of liver disease was not 
significant enough to meet our strict inclusion criteria (n=338); 
index admission was outside our study period (n=63); presence 
of coexisting liver disease (predominantly viral hepatitis; n=61); 
and missing notes (n=7). One-hundred and forty-three individuals 
with an index presentation with decompensated ALD during the 
study period were therefore eligible for inclusion in the study.
Supplementary material S1 shows baseline clinical and 
demographic data in the whole cohort, and the two phases. 
Overall, at admission, five (3.5%) had CPS-A disease, 52 (36.4%) 
had CPS-B and 86 (60.1%) had CPS-C disease, with 75 (52.4%) 
having a MELD score >20. Seventeen (11.9%) were aged 
<40 years and 24 (16.8%) were aged >60 years. Comparing 
admissions in phase 1 and 2 there were no significant differences 
in patient demographics, liver prognostic scores, prevalence of 
cirrhosis-related complications and length of hospital stay.
Data on alcohol units consumed per day were available in 139 
(97.2%) patients, duration of alcohol use in 78 (54.5%) patients 
and nature of alcohol use in 129 (90.2%) patients.
Overall, consumption of beer and cider were significantly lower 
in phase 2 compared to phase 1 (36.3% vs 54.0%, respectively; 
p=0.034; Fig 1a). Over the same time period, there was a slight 
increase in wine and spirits consumption, although this was 
not significant (60.0% vs 52.4%, respectively; p=0.361). The 
percentage with missing data on the type of alcohol consumed 
were not significantly different during phase 1 and 2 (7.9% vs 
11.3%, respectively; p=0.503).
Fig 1b shows the yearly trends in nature of alcohol consumption 
(beer and cider vs wine and spirits) following the introduction of 
the SoS initiative.
Mortality
Overall mortality in the whole cohort (as of May 2018) was 75 
(52.4%) of whom 26 (34.7%) died during the index hospital 
admission (the cause of death being liver-related in all of 
these cases). There was no difference in inpatient mortality 
between phase 1 and phase 2 (19.0% vs 17.5%, respectively; 
p=0.812).
Of the 49 who died after their index hospitalisation, this was 
liver-related in 25 (51%). In the remaining 24 patients, the cause 
of death was unknown: we were unable to access the primary 
healthcare records in 20 and four were referred to the coroner 
without an available outcome.
See supplementary material S2 for univariate analysis 
of baseline demographic and clinical variables associated 
with inpatient mortality during index hospitalisation. There 
was multicollinearity between creatinine, AKI, bilirubin, HE, 
international normalised ratio and the CPS and also between 
sodium, MELD and UKELD scores. Therefore, only the following 
variables were entered into multivariate regression analysis: age, 
gender, duration of alcohol use, CPS, MELD, infection rates and 
ICU stay. The only independent predictor of mortality during 
index hospitalisation was the MELD score (odds ratio 1.25; 95% 
confidence interval 1.03–1.51; p=0.025; Table 2).
Fig 2 shows the KM analysis of overall survival for patients 
admitted in phase 1 and 2. There were no statistically significant 
differences in the two cohorts (p=0.396).
Discussion
This is one of the few published studies in England that attempts 
to assess whether local regulations of alcohol sales influence 
drinking behaviour and hospital admissions in patients with ALD. 
Fig 1. a) Prevalence of consumption of different types of alcohol in 
phases 1 and 2. * = statistically significant, p<0.05. b) Yearly trend in the 
choice of alcohol (as a percentage of patients admitted with alcohol-
related liver disease) following introduction of Sensible on Strength 
initiative. SoS = Sensible on Strength.
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A large longitudinal study in the USA, where researchers 
collected data on type of alcohol sales in 50 states over 12 years, 
found that, after controlling for other covariates, every percentage 
increase in spirit sales was associated with a significant increase 
in cirrhosis mortality rates, no such effect being observed for beer 
or cider.14
Additionally, in Sweden, over two separate time periods, 
reduction in mortality from liver disease between 1969 and 2001 
seems to closely parallel downward trends in sales of spirits but not 
that of beer or wine.15
In contrast, data from Iceland that spans almost 3 decades 
showed the importance of total units of alcohol consumed, rather 
than the type of alcohol, as the main determinant of cirrhosis 
mortality. A lift of the ban on beer sales in 1989 was followed by 
a 30% rise in alcohol intake, this specifically being driven by an 
increase in beer consumption. A drop in the intake of spirits over 
this time period did not prevent the increase in recorded cirrhosis 
mortality in men.16 This corroborates our data suggesting that it is 
the amount rather than the nature of alcohol that determines ALD 
outcomes.
Although outcomes in ALD are gender dependent, we were 
unable to assess this due to the small number of women in 
our cohort.17 However, there was no difference in the gender 
distribution between phase 1 and phase 2 (p=0.835).
Our study focused on the impact of SoS on ALD and drinking 
behaviour, but it is important to be cognisant of the fact that 
moving an already financially deprived cohort away from 
cheap beverages to more expensive drinks could potentially 
have negative social consequences. This needs to be carefully 
addressed in the future when the full impact of the SoS initiative is 
more apparent.
Our study did have limitations. The voluntary nature of this 
public health campaign meant that patients could access 
high-strength drinks from outlets that had not signed up to the 
SoS scheme, which amounted to more than 50% of premises 
during our study period. Secondly, reliably estimating alcohol 
intake retrospectively is fraught with difficulty. As with national 
health surveys, medical histories often rely on personal 
reporting and subjective recall and result in measurement 
errors when people convert alcohol consumption to standard 
units.5 Furthermore, relating health outcomes to drinking 
habits at a single point in time could overlook the effect of 
historical drinking patterns.5 Additionally we only assessed 
the short-term (3-year) impact of the SoS initiative on ALD 
outcome. The natural history of this chronic progressive disease 
might be more accurately observed with a longer follow-up 
period. However, our year-by-year analysis (Fig 2) did not seem 
to elucidate a temporal pattern.
Finally, there were important changes in service delivery during 
the study period that could have impacted our results. Since 
2014, all patients admitted with liver disease were assessed by a 
gastroenterologist/hepatologist within 24 hours, which was not 
the case previously. Also, in 2016, consistent with national trends 
in reduction in addiction services, we lost our dedicated hospital 
alcohol nurses as well as inpatient beds at a local psychiatric 
facility.
In summary, our study shows that while regulating alcohol sales 
can modify drinking behaviour, its impact on the clinical spectrum 
of ALD remains controversial. A complex condition like ALD is likely 
to need a multifaceted intervention. n
Table 2. Multivariate analysis of baseline 
demographic and clinical variables associated with 
inpatient mortality following index hospitalisation 







Age, years 1.09 0.97–1.22 0.140
Gender, male 3.33 0.17–67.5 0.433
Duration of alcohol 
intake, years
1.04 0.97–1.12 0.336
Child–Pugh score 0.64 0.31–1.31 0.224
MELD score 1.25 1.03–1.51 0.025
Presence of infection 2.68 0.27–26.2 0.397
ICU stay, days 4.58 0.17–126 0.369
ICU = intensive care unit; MELD = Model for End-stage Liver Disease.
Though there was a 33% reduction in the consumption of beer 
and cider post introduction of the SOS initiative, the total number 
of alcohol units consumed did not change. This might explain 
why the SOS initiative did not impact the number and severity of 
hospital admissions with ALD nor have an effect on ALD-related 
mortality. In fact, the MELD score remained the only independent 
predictor of inpatient mortality.
Our data lends credence to the existing body of evidence that 
interventions at a population (albeit local) level can modify alcohol 
drinking behaviour.5,13 This is despite the impact of SoS being 
limited to the type of alcohol rather than the total amount of 
alcohol consumed; the impact of the type of alcohol consumed on 
ALD outcomes, in fact, remains controversial.
Fig 2. Kaplan–Meier graph showing overall mortality during phase 1 
and 2 admissions.
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Supplementary material
Additional supplementary material may be found in the online 
version of this article at www.rcpjournals.org/clinmedicine:
S1 – Baseline demographic and clinical data in the whole cohort 
and stratified by admission in phase 1 and 2.
S2 – Univariate analysis of baseline demographic and clinical 
variables associated with inpatient mortality following index 
hospitalisation with decompensated ALD.
References
1 Williams R, Alexander G, Aspinall R  et al. Gathering momentum for 
the way ahead: fifth report of the Lancet Standing Commission on 
Liver Disease in the UK. Lancet 2018;392:2398–412.
2 Burton R, Henn C, Lavoie D  et al. The public health burden of alcohol 
and the effectiveness and cost-effectiveness of alcohol control 
policies: An evidence review. London: Public Health England, 2016.
3 Office for National Statistics. Census 2011: Coastal communi-
ties data. ONS, 2014. https://webarchive.nationalarchives.gov.
uk/20160130200905/http://www.ons.gov.uk/ons/publications/re-
reference-tables.html?edition=tcm%3A77-382072 [Accessed 25 
July 2019].
4 Public Health England. Local alcohol profiles for England. PHE. 
https://fingertips.phe.org.uk/profile/local-alcohol-profiles [Accessed 
25 April 2019].
5 Burton R, Henn C, Lavoie D  et al. A rapid evidence review of the 
effectiveness and cost-effectiveness of alcohol control policies: an 
English perspective. Lancet 2017;389:1558–80.
6 World Health Organization. International classification of diseases, 
10th revision. WHO, 2015.
7 Charif I, Saada K, Mellouki I  et al. Predictors of intra-hospital mor-
tality in patients with cirrhosis. Open J Gastroenterol 2001;4:141–8.
8 Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey M. Diagnosis and 
treatment of alcohol-related liver diseases: 2019 practice guidance 
Address for correspondence: Dr Yazan Haddadin, Brighton 
and Sussex University Hospitals NHS Trust, Royal Sussex 
County Hospital, Eastern Road, Brighton BN2 5BE, UK.  
Email: yazan.haddadin@nhs.net
from the American Association for the Study of Liver Diseases. 
Hepatol 2020;71:306–33.
9 Kamath PS, Wiesner RH, Malinchoc M  et al. A model to pre-
dict survival in patients with end-stage liver disease. Hepatol 
2001;33:464–70.
10 Barber KM, Pioli S, Blackwell JE  et al. Development of a UK score 
for patients with end-stage liver disease. Hepatol 2007;46:611A.
11 Department of Health. UK chief medical officers’ low risk drinking 
guidelines. DoH, 2016. https://assets.publishing.service.gov.uk/ 
government/uploads/system/uploads/attachment_data/
file/545937/UK_CMOs__report.pdf [Accessed 25 July 2019].
12 Lynsdale D (Sensible on Strength initiative responsible officer 
at Brighton & Hove City Council). Personal correspondence. 
Unpublished data.
13 Sharma A, Sinha K, Vandenberg B. Pricing as a means of controlling 
alcohol consumption. 2017. Br Med Bull 2017;123:149–58.
14 Gruenewald PJ, Ponicki WR. The relationship of alcohol sales to cir-
rhosis mortality. J Stud Alcohol 1995;56:635–41.
15 Stokkeland K, Brandt L, Ekbom A, Ösby U, Hultcrantz R. Morbidity 
and mortality in liver diseases in Sweden 1969–2001 in relation to 
alcohol consumption. Scand J Gastroenterol 2006;41:459–64.
16 Tyrfingsson T, Olafsson S, Bjornsson E S, Rafnsson V. Alcohol 
consumption and liver cirrhosis mortality after lifting ban on beer 
sales in country with state alcohol monopoly. Eur J Public Health 
2015;25:729–31.
17 Guy J, Peters M. Liver disease in women: The influence of 
gender on epidemiology, natural history, and patient outcomes. 
Gastroenterol Hepatol 2013;9:633–9.
